Global Waldenstrm Macroglobulinemia (WM) Market Spotlight 2017-2027

News provided by

Research and Markets

15 Feb, 2018, 16:45 GMT

DUBLIN, Feb. 15, 2018 /PRNewswire/ --

The "Market Spotlight: Waldenström Macroglobulinemia (WM)" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Waldenstrm Macroglobulinemia market, comprising key pipeline and marketed drugs, clinical trials, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.


Key Takeaways

  • The author estimates that in 2016, there were approximately 4,600 incident cases of Waldenstrm macroglobulinemia in people aged 40 years and over worldwide, and forecasts that number to increase to 6,000 incident cases by 2025.
  • It is estimated that the majority of diagnosed cases worldwide were males in 2016. Worldwide, the incidence of Waldenstrm macroglobulinemia is highest amongst older individuals aged 60-79 years.
  • Imbruvica, a small molecule tyrosine kinase inhibitor, is the only approved drug by the US Food and Drug Administration for Waldenstrm macroglobulinemia.
  • The majority of industry-sponsored drugs in active clinical development for Waldenstrm macroglobulinemia are in Phase II, with only one drug in Phase III.
  • Therapies in mid-to-late-stage development for Waldenstrm macroglobulinemia focus on targets such as proteasome, Bruton's tyrosine kinase and cluster of differentiation 20. These drugs are administered via the oral, intravenous and subcutaneous routes.
  • There were only two licensing and asset acquisition activities involving Waldenstrm macroglobulinemia drugs during 2012-17. The clinical trials distribution across Phase I-IV indicates that the majority of trials for Waldenstrm macroglobulinemia have been in early and mid-phases of development, with 95.9% of trials in Phase I-II, and only 4.1% in Phase III.
  • The US has a substantial lead in the number of Waldenstrm macroglobulinemia clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.
  • Clinical trial activity in the Waldenstrm macroglobulinemia space is dominated by completed trials.

Key Topics Covered:

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
Chemotherapy
Targeted drugs
Biological therapy or Immunotherapy
Plasmapheresis
Stem cell transplantation (SCT)

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

BIBLIOGRAPHY
Prescription Information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/hpddj2/global_waldenstrm?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets